. . .

Remote Patient Monitoring Gaining Traction

May 2020

'As a group of experts in chronic neurological disorders recently noted in JAMA Neurology, “remote monitoring options, by offering reliable insights into issues that matter most to patients, will empower clinicians in delivering tailor-made counseling to patients via videoconferencing.”’

Satya Nadella, the chief executive of Microsoft, agrees. “There is no turning back, for example in telemedicine,” he said during Microsoft’s April 29, 2020 earnings call. “If you look at even what has happened in this first phase with A.I. bots powering telemedicine triage. That’s going to change, I think, what health-care outcomes look like.'

. . .

Modality Names Tom Sellig to Board of Advisors

April 8, 2020

Modality, a pioneer in AI-backed healthcare screening solutions, announced that it has named Tom Sellig to its Board of Advisors. Mr. Sellig is Chief Executive Office of LabConnect, a leading global provider of central laboratory and support services for biopharmaceutical, pharmaceutical, medical device, and contract research organizations. He also sits on its Board of Directors.

“We are pleased to welcome Tom to Modality,” said David Suendermann-Oeft, Cofounder and Chief Executive Officer of Modality. “His experience in the clinical research space, as well as broader medical technology landscape, will be a tremendous value in helping us optimize how data is collected and used in the research and treatment development process.”

Added Mr. Sellig, ”What Modality is doing with facial and voice recognition data in its AI-powered screens to improve research outcomes is vitally important and highly needed. The cleaner the data, the more accurate the results – and I am excited to join David and his team in delivering that to a wide range of opportunities in digital health today.”

Prior to joining LabConnect, Mr. Sellig served as Chief Commercial Officer at ConnectiveRx and from 2014 to 2018, he was Senior Vice President of Global Sales at Patheon, which was acquired by Thermo Fisher Scientific in 2017. From 2007 to 2014, he held a variety of roles of increasing responsibility within global contract research organization and drug development services company Covance. Before Covance, he had executive leadership roles at Ventana Clinical (now part of Syneos) and Medical Broadcasting Company. He earned his bachelor's degree in Economics from Vanderbilt University and an MBA from New York University.

. . .

Modality Names Four to Board of Advisors

January 22, 2020

Modality named four leading professionals in the medical and healthcare industries to its board of advisors:

  • Dr. Jordan Green, Matina Souretis Horner Professor in Rehabilitation Sciences and Director of Speech and Feeding Disorder Lab and Associate Provost of Research at the MGH Institute of Health Professions at Harvard University
  • Dr. Harneet Bath, Vice President of Inpatient Services at VEP Healthcare
  • Dr. Gloria Lau, CEO and cofounder of Alpha Medical
  • Dr. Irfan Qureshi, Vice President at Biohaven Pharmaceuticals

“Modality is delighted to have such a distinguished group of professionals join our advisory board. Their collective expertise will synergistically help Modality’s automatic speech and facial analytics capabilities to expedite drug trials, reduce the failure rate of trials, and increase the profitability of drugs,” said Dr. David Suendermann-Oeft, CEO and co-founder of Modality. “Their commitment to Modality further confirms the value that we provide to the clinical research space and to the pharmaceutical industry.”

. . .

Modality is featured as one of the five conversational AI companies in the Tooploox AI Trend Report

January, 2020

Modality is featured as one of the five conversational AI companies in the Tooploox AI Trend Report 2020

. . .

Modality.AI's first VC visits the office

January 22, 2020

Voxel Ventures, a Digital Health fund from Frankfurt, Germany, and the first VC to invest in Modality, visited us January 22, 2020 at the San Francisco Office.

Voxel Ventures' Julian Wichmann, Startup Investor & Advisor and Radiologist, MD, said,

"Great meeting yesterday here in San Francisco with the Modality.AI team (a Voxel Ventures portfolio company).

So their fully functional software platform is able to analyze your voice and facial movement in real time, allowing for clinical assessment from home! I tried it out myself and was impressed by the flawless and smooth integration - all you need is a web browser, camera, and internet access (=mobile friendly)! Their #artificialintelligence software is already being tested in clinical trials at a major university hospitals, in which patients with severe neurological diseases can be evaluated at their own pace from home with much more and better data being generated - at a fraction of the cost! Obviously the use cases and business cases for such a system in the future are endless!

True innovation that really helps patients and advances the field is unfortunately hard to find in my opinion when you‘re in #digitalhealth or #healthcare #venturecapital and most #startups often only have an idea for a product. Modality.AI and its brilliant team stood out to me from the beginning and I‘m very excited about their progress and big news in 2020!"

. . .

Modality Announces UCSF Partnership

September 20, 2019

Modality announced its partnership with the University of California, San Francisco’s Weill Institute of Neurosciences at the Alchemist Accelerator’s demo day in Menlo Park on September 20, 2019. Under the terms of the partnership, UCSF researchers are using Modality to help streamline their research process and optimize data collection and analysis.

“We just started using Modality to collect our data, and we can already see it saving us a great deal of time while collecting accurate information,” said Dr. Carly Demopoulos, Assistant Professor of Psychiatry at the Weill Institute. “Our research has become vastly more efficient and I’ve already started planning future studies that are made feasible by Modality.”

Dr. Dempoulos and her team study autism spectrum disorder, particularly characterizing the pathology’s underlying symptoms in order to develop targeted therapies. Autism affects more than 60 million people globally.

Traditionally in research, patients and their caregivers need to go to the lab for interviews, from which speech behaviors are manually recorded, analyzed, and categorized. This has historically been a very cumbersome and labor-intensive process.

“The underlying process to develop drugs and therapies are extremely inefficient,” said David Suendermann-Oeft, CEO and co-founder of Modality. Presently, drug trials take on average six years to complete, according to data from Johns Hopkins University, with 80% failing to secure FDA approval and a spend of roughly $70 billion a year.

“Modality has created a solution,” Dr. Suendermann-Oeft said. “We have created a neurological test that is based on the principle that engages the patient with an avatar in a conversation using the same protocols that the neurologist is using. We are extracting facial movements and speech patterns and producing in real time accurate metrics that are predictive of the clinical outcome.”

As a result, Modality can help close the trials four months earlier, reduce the failure rate by 15%, and increase return on investment in a drug’s investment by 80%.

. . .

Alchemist Accelerator Demo Day

September 20, 2019

Modality.AI Alchemist Accelerator information

. . .